next gen liquid biopsy

Going from the current method of sporadic testing for cancers - to regular monitoring.


Do you know someone
who has cancer?

Then it’s likely detected at a stage where the best possible outcomes are no longer available.

According to the WHO, it is estimated that around 10 million people die from cancer every year, across the globe. For the most prevalent cancers - lung, breast, prostate, and colorectal - we know that if they're detected in the early stages, the chance of survival is more than 90%. So why are so many people not getting the proper help?

The truth about cancer is that the earlier it is detected, the better the chances are of being cured. For several prevalent types of cancers (e.g., breast, lung, ovarian) early detection increases the survival rate after five years to 90% or more, whereas late detection only has a 10-20% survival rate. 
There are many treatments and options - if - your doctor gets the right information, which only happens - if - you get tested for the right thing at the right time. Unfortunately, that rarely happens today as most cancers show no physical symptoms until advanced stages. In other words, detecting and monitoring cancer before it is too late to do something is a huge need and opportunity.

Cancer detection today – the old ways

Cancer detection is still often done by tissue biopsy - an invasive, slow, risky, and expensive method that does not work for early detection. Less than 10 years ago, the first version of a liquid biopsy test was introduced by detecting a few molecular cancer biosignals found in body fluids such as blood, spit, or urine. By using next generation sequencing (NGS), these first-generation liquid biopsy tests demonstrated the huge potential of early, precise, non-invasive, and cost-effective detection of cancer. However, sequencing-based liquid biopsies have significant limitations.
Many of the current commercial liquid biopsy tests rely on a biosignal from sequencing circulating tumor DNA (ctDNA), but that limits the understanding one can gain from the patient as it only provides one perspective on their cancer, and more fundamentally - if there is cancer at all. To truly understand cancer - all types, stages, and treatment choices - much more comprehensive cancer biosignal monitoring will be required.

The current approach with sporadic tests for cancer is simply outdated. We need next gen liquid biopsy to monitor all types of cancer at all stages.

Monitoring cancer biosignals – the next generation of liquid biopsy

Cancer biosignals can be found across the body’s communication networks, but limited technology to detect all kinds of cancer biosignals is stifling progress and innovation in the liquid biopsy market. To advance beyond the limitations of first-generation liquid biopsy, a supplemental or alternative generation of cancer biosignal detection is required.
Current liquid biopsy companies that claim to offer multiomics testing rely on running, in parallel, the same sample through multiple lab instruments or even separate laboratories. For those datasets to be multiomics, those companies must use complex, custom, and costly bioinformatics to merge the different ‘omics’ biosignals back together to be one result, making test improvements and additions of new biosignals either inflexible or impossible.

Cancer biosignals can be found across the body’s communication networks

Using current technologies, it’s virtually impossible to look for all types of cancer biosignals in one patient, not to mention the cost if needing to do it regularly.


Cardea’s BPU™ Platform solves this with its multiomics next gen liquid biopsy platform




Sequencing does not give you the full picture

Accuracy examples on the most successful
sequencing platform in liquid biopsy


Would you deem an 89% risk of missing prostate cancer – or a 69% risk of missing breast cancer - despite taking a test for it, acceptable?

Around 90% of companies in liquid biopsy are using sequencing as their technology.

NGS_PieCharts_01Sequencing alone is not a long-term solution for liquid biopsy. Hence the need for multiomics approaches to get the full picture – the need for next gen liquid biopsy.


The precision of current sequencing-based
multi-cancer early detection
tests is simply unacceptable!



The power of multiomics

If a biomarker is a picture of the current state of some biology, then a biosignal is a video of that state of biology.These biosignals – or ways of communicating – happen in multiple channels inside our bodies – streams like genomics, proteomics, metabolomics, and transcriptomics.
This is true multiomics.
The BPU can read all those types of mutiomics biosignals - in real-time.

Cardea’s proprietary BPU™ (Biosignal Processing Unit) Platform enables a game-changing new generation of more affordable, swift, precise, and comprehensive detection of multiple cancer biosignals. It is the first and only platform able to read all types of biosignals - true multiomics - allowing for detection of any cancer. For example, BPUs can do genomics via nucleic acid biosignals (e.g., ctDNA), proteomics via amino acid biosignals (e.g., immune-response), or even complex intercellular communication biosignals via exosomes – all from the same clinical sample on one platform.

Cardea's BPU offers an all-in-one platform for next gen liquid biopsy 


 The BPU’s ability to detect all types of cancer biosignals in combination with machine learning and AI will result in a breakthrough in protection against cancer via monitoring and timely response - not just sporadic testing. In addition, as BPUs are biocompatible semiconductors built with the nanomaterial graphene, they are small enough to become desktop instruments. Going from testing for single biomarkers via laboratory workflows to monitoring multiple cancer biosignals via one platform is the essence of this next generation of liquid biopsy, which can replace or enhance current liquid biopsy approaches.

Future potential

Cardea’s technological breakthrough offers an innovative and modular development approach to cancer detection as the BPU platform is customizable and open to any new biosignals. Soon doctors and patients will be able to monitor and detect all types and stages of cancer early - finally getting the right information at the right time.
The current approach with sporadic tests for cancer is simply outdated. We need next gen liquid biopsy to monitor all types of cancer at all stages. Cardea’s all-in-one platform for next gen liquid biopsy offers a paradigm shift to move from the current needle in the haystack approach to cancer testing to regularly monitoring all cancer biosignals, so it never becomes too late to achieve the best possible outcome.
Envision the immense potential and societal impact a monthly or quarterly pan-cancer test will have when offered as a monitoring service for all types of cancer - overcoming the multiomics, sensitivity, and selectivity bottlenecks of current cancer detection technologies.

With success over time, Cardea’s BPU has the potential to drastically reduce the number of people who die of cancer every year. By detecting all cancers early - that's over a 90% survival rate -with our partners we have the potential to reduce the global number of people dying from cancer from 10 to 1 million every year.

Are you ready to make a difference?